Corbus Pharmaceuticals (NASDAQ:CRBP)‘s stock had its “buy” rating restated by investment analysts at Noble Financial in a report issued on Friday.

A number of other equities research analysts also recently commented on CRBP. BidaskClub upgraded Corbus Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, August 25th. ValuEngine downgraded Corbus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, September 13th. Finally, Cantor Fitzgerald restated a “buy” rating and issued a $24.00 target price on shares of Corbus Pharmaceuticals in a research report on Wednesday, September 20th. Two equities research analysts have rated the stock with a sell rating and three have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $25.00.

Corbus Pharmaceuticals (NASDAQ CRBP) traded down $0.15 during trading hours on Friday, reaching $7.15. The company’s stock had a trading volume of 1,687,830 shares, compared to its average volume of 553,893. Corbus Pharmaceuticals has a 12 month low of $5.30 and a 12 month high of $10.50.

Corbus Pharmaceuticals (NASDAQ:CRBP) last posted its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.14) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.16) by $0.02. Corbus Pharmaceuticals had a negative return on equity of 96.02% and a negative net margin of 1,040.41%. The company had revenue of $0.80 million for the quarter. equities research analysts expect that Corbus Pharmaceuticals will post -0.61 EPS for the current fiscal year.

In other news, Director David P. Hochman acquired 10,000 shares of the company’s stock in a transaction dated Friday, November 10th. The stock was acquired at an average cost of $7.08 per share, with a total value of $70,800.00. Following the completion of the purchase, the director now owns 459,500 shares of the company’s stock, valued at approximately $3,253,260. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director David P. Hochman acquired 5,000 shares of the company’s stock in a transaction dated Monday, November 13th. The stock was purchased at an average cost of $6.90 per share, with a total value of $34,500.00. The disclosure for this purchase can be found here. Insiders bought 25,336 shares of company stock valued at $175,632 over the last ninety days. Insiders own 11.90% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CRBP. State Board of Administration of Florida Retirement System acquired a new position in Corbus Pharmaceuticals during the 3rd quarter worth $108,000. Yellowstone Partners LLC acquired a new position in Corbus Pharmaceuticals during the 3rd quarter worth $110,000. Voya Investment Management LLC acquired a new position in Corbus Pharmaceuticals during the 2nd quarter worth $125,000. Capital Fund Management S.A. acquired a new position in Corbus Pharmaceuticals during the 2nd quarter worth $130,000. Finally, Credit Suisse AG acquired a new position in Corbus Pharmaceuticals during the 1st quarter worth $157,000. 27.84% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This story was first published by American Banking News and is the property of of American Banking News. If you are accessing this story on another publication, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/12/16/corbus-pharmaceuticals-crbp-buy-rating-reaffirmed-at-noble-financial.html.

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment.

Receive News & Ratings for Corbus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.